Preview

Problems of Endocrinology

Advanced search

The short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment

https://doi.org/10.14341/probl13150

Abstract

BACKGROUND: Differential diagnosis between the normocalcemic primary hyperparathyroidism (nPHPT) and secondary hyperparathyroidism (SHPT) due to hypercalciuria remains a challenge.

AIM: The aim of this study was to investigate the capability of short test with hydrochlorothiazide for the differential diagnosis of nPHPT and SHPT.

MATERIALS AND METHODS: A retrospective study was conducted with the participation of 28 patients who underwent a functional test with thiazide diuretics during hospitalization in the Department of parathyroid glands pathology and mineral disorders of the Endocrinology Research Centre, Russia. Parameters of mineral metabolism were evaluated before and 3–5 days after taking hydrochlorothiazide 50 mg/day.

RESULTS: According to baseline and dynamic biochemical evaluation patients were divided into 3 groups. Group 1 (n=21) included patients with confirmed PHPT, who reached hypercalcemia accompanying with an elevated level of iPTH (n=19) or an increased level of iPTH accompanying with normocalcemia (n=2). In group 1, baseline Caadj. was 2.48 mmol/l [2.47; 2.52], iPTH 107.5 pg/ml [86.8; 133.0], after short test — 2.63 mmol/l [2.59; 2.66] and 102.1 pg/ml [95,7; 124,1]. Group 2 included only one who was diagnosed with SHPT, a normal value of iPTH with concomitant normocalcemia was achieved after 4 days of hydrochlorothiazide therapy (baseline Caadj. 2.35 mmol/l, iPTH 74.5 pg/ml vs at 2.27 mmol/l and 50.7 pg/ml respectively). Patients with doubtful results of the test entered in group 3 (n=6), they did not achieve significant changes in the calcium and iPTH levels, so it was recommended to continue the test on an outpatient basis (baseline Caadj. 2.39 mmol/l [2.33;2.45], iPTH 97.0 pg/ml [83.1;117.0]); after short test — 2.47 mmol/l [2.42; 2.48] and 91.3 pg/ml [86.9; 124.0] respectively). Groups with PHPT and SHPT and doubtful results significantly differed from each other in Caadj (р=0.003, U-test, Bonferroni correction Р0=0.006), but not in iPTH, daily calciuria, eGFR, and phosphorus. There were no significant differences in the incidence of classical complications of PHPT.

CONCLUSION: The diagnosis of PHPT was confirmed in 21/28 patients 3–5 days after taking hydrochlorothiazide 50 mg/day. The obtained results are significant for the differential diagnosis in hospitalized patients with an unspecified genesis of hyperparathyroidism.

About the Authors

A. K. Eremkina
Endocrinology Research Centre
Russian Federation

Anna K. Eremkina - MD, PhD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 8848-2660


Competing Interests:

None



A. R. Elfimova
Endocrinology Research Centre
Russian Federation

Alina R. Ajnetdinova.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 9617-7460


Competing Interests:

None



E. A. Aboisheva
Endocrinology Research Centre
Russian Federation

Elizaveta A. Aboisheva - MD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 3828-3502


Competing Interests:

None



E. V. Karaseva
Endocrinology Research Centre
Russian Federation

Elena V. Karaseva - MD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 5837-2136


Competing Interests:

None



M. I. Fadeeva
Endocrinology Research Centre
Russian Federation

Mariya I. Fadeeva - MD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 8647-2286


Competing Interests:

None



I. S. Maganeva
Endocrinology Research Centre
Russian Federation

Irina S. Maganeva - MD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 2575-3091


Competing Interests:

None



E. V. Kovaleva
Endocrinology Research Centre
Russian Federation

Elena V. Kovaleva – MD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 7387-6791


Competing Interests:

None



A. M. Gorbacheva
Endocrinology Research Centre
Russian Federation

Anna M. Gorbacheva - MD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 9815-7509


Competing Interests:

None



E. E. Bibik
Endocrinology Research Centre
Russian Federation

Ekaterina E. Bibik - MD.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 8522-9466


Competing Interests:

None



N. G. Mokrysheva
Endocrinology Research Centre
Russian Federation

Natalia G. Mokrysheva - MD, PhD, Professor.

11 Dm.Ulyanova street, 117036 Moscow.

SPIN-код: 5624-3875


Competing Interests:

None



References

1. Bollerslev J, Rejnmark L, Zahn A, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021). Eur J Endocrinol. 2022;186(2):R33-R63. doi: https://doi.org/10.1530/EJE-21-1044

2. Mokrysheva NG, Eremkina AK, Mirnaya SS, et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. doi: https://doi.org/10.14341/probl12801

3. Eisner BH, Ahn J, Stoller ML. Differentiating Primary from Secondary Hyperparathyroidism in Stone Patients: The “Thiazide Challenge.” J Endourol. 2009;23(2):191-192. doi: https://doi.org/10.1089/end.2008.0567

4. Mirnaya SS, Eremkina AK. Hypercalciuria and hyperparathyroidism — is there always a connection? Obe Metab. 2022;19(1):92-95. doi: https://doi.org/10.14341/omet12788

5. Edwards A, Bonny O. A model of calcium transport and regulation in the proximal tubule. Am J Physiol Physiol. 2018;315(4):F942-F953. doi: https://doi.org/10.1152/ajprenal.00129.2018

6. Alexander RT, Dimke H. Effect of diuretics on renal tubular transport of calcium and magnesium. Am J Physiol Physiol. 2017;312(6):F998-F1015. doi: https://doi.org/10.1152/ajprenal.00032.2017

7. Corbetta S. Normocalcemic Hyperparathyroidism. Front Horm Res. 2019;51:23-39. doi: https://doi.org/10.1159/000491036

8. Coe FL, Canterbury JM, Firpo JJ, Reiss E. Evidence for Secondary Hyperparathyroidism in Idiopathic Hypercalciuria. J Clin Invest.

9. Coffey RJ, Lee TC, Canary JJ. The Surgical Treatment of Primary Hyperparathyroidism. Ann Surg. 1977;185(5):518-523. doi: https://doi.org/10.1097/00000658-197705000-00003

10. Griebeler ML, Kearns AE, Ryu E, et al. Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. J Clin Endocrinol Metab. 2016;101(3):1166-1173. doi: https://doi.org/10.1210/jc.2015-3964


Supplementary files

1. Figure 1. The division of patients into groups according to the results of the study.
Subject
Type Исследовательские инструменты
View (258KB)    
Indexing metadata ▾

Review

For citations:


Eremkina A.K., Elfimova A.R., Aboisheva E.A., Karaseva E.V., Fadeeva M.I., Maganeva I.S., Kovaleva E.V., Gorbacheva A.M., Bibik E.E., Mokrysheva N.G. The short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment. Problems of Endocrinology. 2022;68(4):52-58. (In Russ.) https://doi.org/10.14341/probl13150

Views: 1883


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)